- Home
- BX vs TOVX Comparison
BX vs TOVX Comparison
Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BX | TOVX |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4B | 6.4M |
| IPO Year | 2007 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BX | TOVX |
|---|---|---|
| Price | $107.91 | $0.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 1 |
| Target Price | ★ $165.50 | N/A |
| AVG Volume (30 Days) | 8.1M | ★ 8.5M |
| Earning Date | 04-16-2026 | 03-12-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | 6.91 | ★ 89.07 |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $21.82 | N/A |
| P/E Ratio | $27.90 | ★ N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.73 | $0.16 |
| 52 Week High | $190.09 | $1.50 |
Technical Indicators
Market Signals| Indicator | BX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 62.99 |
| Support Level | $103.41 | $0.17 |
| Resistance Level | $165.14 | $0.22 |
| Average True Range (ATR) | 4.09 | 0.02 |
| MACD | 1.15 | 0.00 |
| Stochastic Oscillator | 39.73 | 43.94 |
Price Performance
Historical ComparisonAbout BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.